David Wofsy, MD

David Wofsy, MD

Education
2017 - Diversity, Equity, and Inclusion Champion Training, University of California
Residency, - School of Medicine, University of California, San Francisco
Honors and Awards
  • Master of the American College of Rheumatology, American College of Rheumatology, 2012
  • Paul Klemperer Award and Medal, New York Academy of Medicine, 2011
  • Lee C. Howley Sr. Prize, Arthritis Foundation, 2007
  • Arthritis Hero Award, Arthritis Foundation, 2001
  • Edmund L. Dubois Award for Outstanding Research in SLE, American College of Rheumatology, 1999
Websites
Publications

  1. Lu R, Wagner CA, Fava A, Jones B, Izmirly P, Belmont HM, Clancy RM, Anolik J, Barnas JL, Putterman C, Wofsy D, Weisman MH, Davidson A, Fine DM, Holers VM, Utz PJ, Accelerating Medicines Partnership in RA/SLE Network, Diamond B, Buyon J, Petri M, Guthridge JM, James JA. Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment response. bioRxiv : the preprint server for biology 2026. PMID: 42182176


  2. Hoover PJ, Eisenhaure TM, Hodgin J, Apruzzese W, Mears J, Peters M, Jones T, Shah SI, Kamal H, Leavitt R, Jackson SW, Danaher P, Rao DA, Xiao Q, Gurajala S, Ai J, Fava A, Berthier CC, Horisberger A, Barnas JL, Izmirly PM, Belmont HM, Clancy R, Furie R, Aranow C, Guthridge JM, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, McMahon MA, Grossman J, Payan-Schober F, Hildeman DA, Woodle ES, Putterman C, Kretzler M, Clark MR, Raychaudhuri S, James JA, Anolik JH, Petri MA, Buyon JP, Accelerating Medicines Partnership (AMP) RA/SLE Network, Diamond B, Davidson A, Hacohen N, Arazi A. Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression. Annals of the rheumatic diseases 2026. PMID: 42055919


  3. Sugiarto NW, Gurajala S, Curtis M, Eisenhaure TM, Arazi A, Fava A, Xiao Q, Mears J, Rovin B, Berthier CC, Zhao Y, Izmirly PM, Barnas JL, Hoover PJ, Peters M, Raychowdhury R, Horisberger A, Sakaue S, Furie RA, Belmont HM, Hildeman DA, Woodle ES, Dall'Era M, Putterman C, Kamen DL, McMahon MA, Grossman J, Kalunian KC, Hodgin JB, Payan-Schober F, Apruzzese W, Perlman H, Cuda CM, Wofsy D, Guthridge JM, Anolik JH, James JA, Accelerating Medicines Partnerships Rheumatoid Arthritis/Systemic Lupus Erythematosus , Rao DA, Davidson A, Petri MA, Buyon JP, Hacohen N, Diamond B, Raychaudhuri S. A population-scale atlas of blood and tissue in lupus nephritis. bioRxiv : the preprint server for biology 2026. PMID: 41959244


  4. Fava A, Wagner CA, Guthridge CJ, Macwana S, DeJager W, Munroe ME, Izmirly P, Belmont HM, Diamond B, Davidson A, Utz PJ, Weisman MH, Carlucci PM, Dall'Era M, Kalunian K, Putterman C, Anolik J, Barnas JL, Wofsy D, Kamen D, Furie RA, Rao DA, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Petri M, Guthridge JM, Buyon J, James JA. Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment. Arthritis care & research 2025. PMID: 41048053


  5. Hoover PJ, Raparia C, Lieb DJ, Tzur Y, Kang J, Arazi A, Leavitt R, Mishra R, Shah SI, Simmons D, Li S, Peters M, Eisenhaure T, Few-Cooper TJ, Gurajala SS, Sonny A, Hodgin JB, Berthier CC, Guthridge JM, Fava A, Clancy RM, Putterman C, Izmirly PM, Belmont HM, Kalunian K, Kamen D, Wofsy D, Buyon JP, James JA, Petri M, Diamond B, Raychaudhuri S, Shen-Orr SS, Accelerating Medicines Partnership in RA/SLE network, Hacohen N, Davidson A. A human-mouse atlas of intrarenal myeloid cells identifies conserved disease-associated macrophages in lupus nephritis. The Journal of experimental medicine 2025. PMID: 40900124


  6. van Dooren HJ, van Schaik M, Dorjée AL, Arends EJ, Mackay M, Laura C, Fox DA, Wofsy D, Smilek D, Aranow C, Dall'Era M, Huizinga TWJ, van Kooten C, Toes REM, Diamond B, Teng YKO, Suurmond J. Differences in dynamics of specific anti-nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2025. PMID: 40356198


  7. Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. The Journal of clinical investigation 2025. PMID: 40536813


  8. Anders HJ, Chan TM, Sanchez-Guerrero J, Wofsy D, Bensley K, Kim L, Hung Lo K, Shu C, Shao J, Karyekar CS, Diamond B. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a Phase 2, randomized, placebo-controlled study. Rheumatology (Oxford, England) 2024. PMID: 39673415


  9. Chu D, Schwartz N, Ampudia J, Guthridge J, James J, Buyon JP, Connelly S, Fung M, Ng CT, Accelerating Medicines Partnership: RA/SLE Network
    , Fava A, Petri M, Mohan C, Putterman C. Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis. Rheumatology (Oxford, England) 2025. PMID: 39404817


  10. Carlucci PM, Preisinger K, Deonaraine KK, Zaminski D, Dall'Era M, Gold HT, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao D, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Izmirly PM, Buyon J, Petri M. Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network. Rheumatology (Oxford, England) 2024. PMID: 38530774


  11. Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership: RA/SLE Network, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv : the preprint server for biology 2024. PMID: 38293222


  12. Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao DA, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Petri M, Buyon J, Furie R. Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. Arthritis research & therapy 2024. PMID: 38378664


  13. Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, Rao DA, Arazi A, Celia AI, Putterman C, Anolik JH, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James JA, Guthridge J, Atta MG, Monroy Trujillo J, Fine D, Clancy R, Belmont HM, Izmirly P, Apruzzese W, Goldman D, Berthier CC, Hoover P, Hacohen N, Raychaudhuri S, Davidson A, Diamond B, Accelerating Medicines Partnership in RA/SLE network, Petri M. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI insight 2024. PMID: 38258904


  14. Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, Apruzzese W, Belmont HM, Izmirly PM, Zaminski D, Wu M, Connery S, Payan-Schober F, Furie R, Dall'Era M, Cho K, Kamen D, Kalunian K, Anolik J, Barnas J, Ishimori M, Weisman MH, Accelerating Medicines Partnership (AMP) RA/SLE Network, Buyon JP, Petri M. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. AAOHN journal : official journal of the American Association of Occupational Health Nurses 2022. PMID: 35212719


  15. Fava A, Rao DA, Mohan C, Zhang T, Rosenberg A, Fenaroli P, Belmont HM, Izmirly P, Clancy R, Monroy Trujillo J, Fine D, Arazi A, Berthier CC, Davidson A, James JA, Diamond B, Hacohen N, Wofsy D, Raychaudhuri S, Apruzzese W, Accelerating Medicines Partnership in RA/SLE network, Buyon J, Petri M. Urine Proteomics and Renal Single Cell Transcriptomics Implicate IL-16 in Lupus Nephritis. AAOHN journal : official journal of the American Association of Occupational Health Nurses 2021. PMID: 34783463


  16. Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH, Accelerating Medicines Partnership RA/SLE network , Petri MA, Buyon JP. Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus science & medicine 2021. PMID: 34389634


  18. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Lim SS, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis & rheumatology (Hoboken, N.J.) 2020. PMID: 32755035


  19. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the rheumatic diseases 2020. PMID: 32816709


  20. Wofsy D. A Tale of Two Trials. Arthritis & rheumatology (Hoboken, N.J.) 2020. PMID: 32182394


  21. Fava A, Buyon JP, Mohan C, Zhang T, Belmont HM, Izmirly P, Clancy R, Monroy Trujillo J, Fine DM, Zhang Y, Magder L, Rao DA, Arazi A, Berthier CC, Davidson A, Diamond B, Hacohen N, Wofsy D, Apruzzese W, Accelerating Medicines Partnership T, Raychaudhuri S, Petri M. Integrated urine proteomics and renal single-cell genomics identify an interferon-? response gradient in lupus nephritis. JCI insight 2020. PMID: 32396533


  22. Busche K, Elks ML, Hanson JT, Jackson-Williams L, Manuel RS, Parsons WL, Wofsy D, Yuan K. The Validity of Scores from the New MCAT Exam in Predicting Student Performance: Results from a Multisite Study. Academic medicine : journal of the Association of American Medical Colleges 2019. PMID: 31425189


  23. Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM, Izmirly P, Wofsy D, Hacohen N, Diamond B, Putterman C, Davidson A. The Accelerating Medicines Partnership - Organizational Structure and Preliminary Data from the Phase 1 Studies of Lupus Nephritis. Arthritis care & research 2019. PMID: 31502417


  24. Henderson MC, Jerant A, Unkart J, Griffin EJ, Sciolla SF, Kelly CJ, Peterson EM, Hall T, Wofsy D, Fancher TL. The Relationships among Self-Designated Disadvantage, Socioeconomic Disadvantage, and Academic Performance in Medical School: A Multi-Institutional Study. AAOHN journal : official journal of the American Association of Occupational Health Nurses 2020. PMID: 35061622


  25. Craft JE, Crow MK, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin JA, Koopman WJ, Lockshin MD, Salmon JE, Seaman WE, Sergent JS, Uknis AB, Weinblatt ME, Wofsy D. Georgia Abortion Law and our Commitment to Patients. Arthritis & rheumatology (Hoboken, N.J.) 2019. PMID: 31637878


  26. Rao DA, Arazi A, Wofsy D, Diamond B. Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis. Nature reviews. Nephrology 2019. PMID: 31853010


  27. Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise E, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Petri M, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond B, Anolik JH, Mackey MF, Alves SE, Nigrovic PA, Costenbader KH, Brenner MB, Lederer JA, Rao DA. PD-1hi CXCR5- T peripheral helper cells promote B cells responses in lupus via MAF and IL-21. JCI insight 2019. PMID: 31536480


  28. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis. Nature immunology 2019. PMID: 31409923


  29. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2019. PMID: 31385462


  30. Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P. Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatology advances in practice 2019. PMID: 31528843


  31. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the rheumatic diseases 2019. PMID: 31383717


  32. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. The immune cell landscape in kidneys of patients with lupus nephritis. Nature immunology 2019. PMID: 31209404


  33. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Tancredi DJ, Sousa FJ, Franks P. Do Admissions Multiple Mini-Interview and Traditional Interview Scores Predict Subsequent Academic Performance? A Study of Five California Medical Schools. Academic medicine : journal of the Association of American Medical Colleges 2018. PMID: 30188370


  34. Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the rheumatic diseases 2019. PMID: 30692164


  35. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD. Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2018. PMID: 30277008


  36. Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M. Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. The Journal of rheumatology 2018. PMID: 30554156


  37. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools? Academic medicine : journal of the Association of American Medical Colleges 2018. PMID: 29561273


  38. Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P. Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study. Academic medicine : journal of the Association of American Medical Colleges 2017. PMID: 29095170


  39. Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L. Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. Kidney international reports 2018. PMID: 30197972


  41. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Volume 70 of Issue 4. 2018. PMID: 28692774


  42. Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools. Volume 17 of Issue 1. 2017. PMID: 29110662


  43. Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D. Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Volume 4 of Issue 1. 2017. PMID: 29214037


  44. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Volume 69 of Issue 1. Arthritis & rheumatology (Hoboken, N.J.) 2016. PMID: 27390168


  45. Wofsy D. In memoriam: Ephraim P. Engleman, MD, 1911-2015. Volume 67 of Issue 11. Arthritis & rheumatology (Hoboken, N.J.) 2015. PMID: 26508466


  46. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Volume 2 of Issue 1. 2015. PMID: 26023331


  47. Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Volume 67 of Issue 5. Arthritis & rheumatology (Hoboken, N.J.) 2015. PMID: 25779381


  49. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Volume 65 of Issue 6. Arthritis and rheumatism 2013. PMID: 23529285


  51. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Volume 64 of Issue 11. Arthritis and rheumatism 2012. PMID: 22806274


  52. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. Volume 365 of Issue 20. The New England journal of medicine 2011. PMID: 22087680


  53. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. Volume 38 of Issue 5. 2011. PMID: 21285160


  54. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Volume 63 of Issue 3. 2010. PMID: 21080348


  55. Papadakis MA, Wofsy D. Plagiarism on personal statements: a disturbing symptom of a broader trend. Volume 153 of Issue 2. Annals of internal medicine 2010. PMID: 20643994


  56. Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Volume 6 of Issue 3. 2010. PMID: 20197774


  57. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Volume 9 of Issue 44. 2010. PMID: 20102681


  59. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Volume 49 of Issue 1. 2009. PMID: 19933596


  60. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Volume 5 of Issue 10. 2009. PMID: 19798031


  61. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Volume 5 of Issue 6. 2009. PMID: 19491915


  62. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Volume 20 of Issue 5. Journal of the American Society of Nephrology : JASN 2009. PMID: 19369404


  63. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. Volume 301 of Issue 13. JAMA 2009. PMID: 19336712


  64. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E. A quality indicator set for systemic lupus erythematosus. Volume 61 of Issue 3. Arthritis and rheumatism 2009. PMID: 19248127


  65. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Volume 56 of Issue 12. Arthritis and rheumatism 2007. PMID: 18050206


  66. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Volume 16 of Issue 12. 2007. PMID: 18042591


  67. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Volume 18 of Issue 5. 2006. PMID: 16896285


  68. Daikh DI, Gillis J, Wofsy D. Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Volume 55 of Issue 2. Arthritis and rheumatism 2006. PMID: 16583382


  69. Wofsy D. Living in a different world. Volume 52 of Issue 2. Arthritis and rheumatism 2005. PMID: 15692996


  70. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Volume 14 of Issue 3. 2005. PMID: 15807196


  71. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Volume 46 of Issue 12. Arthritis and rheumatism 2002. PMID: 12483729


  72. Wofsy D, Daikh DI. Treatment of autoimmune diseases by inhibition of T-cell costimulation. Volume 12 of Issue 1. 2002. PMID: 24383824


  73. Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis and rheumatism 2001. PMID: 11508422


  74. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. Journal of immunology (Baltimore, Md. : 1950) 2001. PMID: 11207238


  75. Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V. Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets. Kidney international 2001. PMID: 11168938


  76. Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. The Journal of rheumatology 2001. PMID: 11196549


  77. Daikh DI, Wofsy D. Treatment of autoimmunity by inhibition of T cell costimulation. Advances in experimental medicine and biology 2001. PMID: 11505969


  78. Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ. The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G. Immunology 1999. PMID: 10583610


  79. Daikh DI, Wofsy D. Effects of anti-B7 monoclonal antibodies on humoral immune responses. Volume 12 of Issue 2. 1999. PMID: 10047430


  80. Daikh DI, Wofsy D. On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Volume 30 of Issue 8. 1998. PMID: 9865285


  81. Wofsy D, Daikh DI. Opportunities for future biological therapy in SLE. Volume 12 of Issue 3. 1998. PMID: 9890111


  82. Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Volume 87 of Issue 1. 1998. PMID: 9576007


  83. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Volume 159 of Issue 7. Journal of immunology (Baltimore, Md. : 1950) 1997. PMID: 9317105


  84. Daikh D, Wofsy D, Imboden JB. The CD28-B7 costimulatory pathway and its role in autoimmune disease. Volume 62 of Issue 2. 1997. PMID: 9261329


  85. Adleman LM, Wofsy D. Blind T-cell homeostasis in CD4-deficient mice. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996. PMID: 8601219


  86. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Volume 265 of Issue 5176. 1994. PMID: 7520604


  87. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. Volume 94 of Issue 2. The Journal of clinical investigation 1994. PMID: 8040314


  90. Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection . Journal of acquired immune deficiency syndromes 1993. PMID: 8094457


  91. Wofsy D. Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunology series 1993. PMID: 8096400


  92. Finck BK, Yung CM, Carteron NL, Wofsy D. The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies. Clinical immunology and immunopathology 1992. PMID: 1360341


  93. Connolly K, Roubinian JR, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. Volume 149 of Issue 9. Journal of immunology (Baltimore, Md. : 1950) 1992. PMID: 1357036


  94. Jäck HM, Beck-Engeser G, Lee G, Wofsy D, Wabl M. Tumorigenesis mediated by an antigen receptor. Proceedings of the National Academy of Sciences of the United States of America 1992. PMID: 1528851


  95. Wofsy D, Carteron NL. CD4 antibody therapy in systemic lupus erythematosus. Volume 2 of Issue 6. 1990. PMID: 2104279


  97. Wofsy D. Regulation of immunity by anti-T-cell antibodies. The Western journal of medicine 1990. PMID: 2219889


  98. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. Volume 144 of Issue 5. Journal of immunology (Baltimore, Md. : 1950) 1990. PMID: 2307839


  99. Ermak TH, Steger HJ, Wofsy D. Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node. Laboratory investigation; a journal of technical methods and pathology 1989. PMID: 2529396


  100. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Volume 52 of Issue 3. 1989. PMID: 2758698


  101. Erlich KS, Wofsy D, Dix RD, Mills J. Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Volume 52 of Issue 2. 1989. PMID: 2525439


  102. Carteron NL, Schimenti CL, Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. Volume 142 of Issue 5. Journal of immunology (Baltimore, Md. : 1950) 1989. PMID: 2521880


  103. Klippel JH, Strober S, Wofsy D. New therapies for the rheumatic diseases. Bulletin on the rheumatic diseases 1989. PMID: 2670022


  105. Wofsy D. The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus. Volume 1 of Issue 2. 1988. PMID: 2978113


  106. Carteron NL, Wofsy D, Seaman WE. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. Volume 140 of Issue 3. Journal of immunology (Baltimore, Md. : 1950) 1988. PMID: 2448372


  107. Seaman WE, Wofsy D. Selective manipulation of the immune response in vivo by monoclonal antibodies. Annual review of medicine 1988. PMID: 3285774


  108. Wofsy D. Treatment of autoimmune diseases with monoclonal antibodies. Progress in allergy 1988. PMID: 3064092


  109. Wofsy D. New approaches to treating systemic lupus erythematosus. The Western journal of medicine 1987. PMID: 3310402


  110. Wofsy D, Chiang NY. Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice. European journal of immunology 1987. PMID: 2954827


  111. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. Journal of immunology (Baltimore, Md. : 1950) 1987. PMID: 3106478


  112. Gutstein NL, Wofsy D. Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3097122


  113. Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. Transplantation 1986. PMID: 2947360


  114. Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3090139


  115. Wofsy D. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. Volume 136 of Issue 12. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3086436


  116. Stanton T, Stevens TL, Ledbetter JA, Wofsy D. Anti-Ly-1 antibody induces interleukin 2 release from T cells. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3081630


  118. Wofsy D. Strategies for treating autoimmune disease with monoclonal antibodies. The Western journal of medicine 1985. PMID: 3911593


  119. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. Journal of immunology (Baltimore, Md. : 1950) 1985. PMID: 3928743


  120. Wofsy D, Mayes DC, Woodcock J, Seaman WE. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. Journal of immunology (Baltimore, Md. : 1950) 1985. PMID: 3160776


  121. Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. The Journal of experimental medicine 1985. PMID: 3919141


  122. Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. Treatment of murine lupus with monoclonal anti-T cell antibody. Volume 134 of Issue 2. Journal of immunology (Baltimore, Md. : 1950) 1985. PMID: 3871218


  123. Wofsy D. [Not Available]. Volume 5 of Issue 7. 1984. PMID: 25289950


  124. Wofsy D. Hormones, handedness, and autoimmunity. Volume 5 of Issue 6. 1984. PMID: 25289744


  126. Wofsy D, Kerger CE, Seaman WE. Monocytosis in the BXSB model for systemic lupus erythematosus. The Journal of experimental medicine 1984. PMID: 6363600


  127. Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. Journal of immunology (Baltimore, Md. : 1950) 1983. PMID: 6187819


  128. Shear HL, Wofsy D, Talal N. Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. Clinical immunology and immunopathology 1983. PMID: 6872348


  129. Talal N, Dauphinee MJ, Wofsy D. Interleukin-2 deficiency, genes, and systemic lupus erythematosus. Volume 25 of Issue 7. Arthritis and rheumatism 1982. PMID: 6285934


  130. Wofsy D, Ledbetter JA, Roubinian JR, Seaman WE, Talal N. Thymic influences on autoimmunity in MRL-lpr mice. Scandinavian journal of immunology 1982. PMID: 6981841


  131. Dauphinée MJ, Kipper SB, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. Journal of immunology (Baltimore, Md. : 1950) 1981. PMID: 6975325


  132. Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. The Journal of experimental medicine 1981. PMID: 6975351


  133. Wofsy D, Dauphinée MJ, Kipper SB, Talal N. Interleukin-2 deficiency in murine systemic lupus erythematosus. Transactions of the Association of American Physicians 1981. PMID: 6979821


  135. Loeb JM, Livermore BM, Wofsy D. Coccidioidomycosis of the thyroid. Annals of internal medicine 1979. PMID: 475170